EHA 2024 | Real-world comparison of TTNT with ibrutinib or acalabrutinib in CLL
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute, Charlotte, NC, presents the findings of a real-world data analysis comparing the time to next treatment (TTNT) between first-line ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia (CLL). Overall, both patient groups exhibited encouraging results, with the majority not requiring the initiation of a new therapy. However, there was a significantly shorter TTNT in the acalabrutinib group, including in the high-risk patient subgroup harboring chromosome 17 aberrations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
